NASDAQ · NEPH
Nephros, Inc.
Healthcare · Medical - Instruments & Supplies
$4.23▲ 2.17% ($0.09)at close
After hours$4.32▲ 2.13%4:36 PM ET
Valuation
Revenue & margin DCF
Verdict: expensive. Price above all scenarios.
The price needs 21.0% revenue growth a year for 10 years. Our scenarios assume 12.7–21.9%.
That's 1.3× its past 4-year pace.
Value per share
Base case
$3.57
Price used $4.23 is 18% above this
USD · TTM ending Jun 30, 2026 · Price Sep 25, 8:00 PM UTC
Revenue each value needs
Revenue today $20.7M. The price needs $140M by 2036. Base case: $105M. At its recent pace: $95M. Bear to Bull: $68.3M to $151M.
Revenue today $20.7M. The price needs $140M by 2036. Base case: $105M. At its recent pace: $95M. Bear to Bull: $68.3M to $151M.
Revenue in 2036
today $20.7M
+$35.2Mmore than the Base case · 1.3×
Value per share · Base case
$3.57
Price $4.23
18% above this
- 10-yr revenue CAGR
- 17.6%
- Ending operating margin
- 9.7%
- Discount rate
- 13.5%
USD · TTM ending Jun 30, 2026 · Price Sep 25, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 1.2% over the last year. Revenue grew 24.2% over the trailing twelve months. Operating margin moved from 8.01% to 7.92%. Free cash flow declined 133.1% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher with no clear directional signal from operating metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 7.92%. A decisive move in revenue — currently up 24.2% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors.
Market multiples
Stock splits
Every 9 shares became 1
Every 20 shares became 1
Profitability & growth
Analyst consensus
4
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 5, 2026
Q4 FY26 · EPS est $0.02 · Revenue est $5.49M
View
Institutional Sentiment
Nephros, Inc. · NEPH
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.